Announced
Completed
Financials
Tags
hard-to-treat diseases
United Kingdom
Acquisition
Private Equity
Friendly
Single Bidder
protective antibodies
Biotechnology
Minority
Private
Cross Border
Venture Capital
Completed
Synopsis
RA Capital Management, an American investment firm based in Boston, led a £60m funding round in Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, with participation from Lightstone Ventures, Dementia Discovery, SV Health Investors, Data Collective VC and DHVC. “Our aim is to become a major player in the identification of novel targets and antibodies in the areas of neurodegeneration and cancer. The substantial financial commitment by this high-caliber group of US and European investors is a strong endorsement of our science and team,” Alex Leech, Alchemab CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.